PRPO Precipio, Inc.
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a…
Industry Peers
Diagnostics & Research| Headline | Source | Time |
|---|---|---|
Older | ||
 PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now? Precipio and Fulgent Genetics differ in business scope, valuation and growth drivers, but which cancer diagnostics stock looks more compelling now? Let's dive in. | ||
 The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Abbott, NLI and Precipio Goldman Sachs, RTX and Abbott lead Zacks' latest research, with growth drivers balanced by costs, supply-chain and market risks. | ||
 Top Research Reports for Goldman Sachs, RTX & Abbott Goldman Sachs, RTX and Abbott headline today's research, with growth drivers, risks and strategic moves shaping their outlooks. | ||
 PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more compelling now? Let's dive in. | ||
 Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong PRPO's second-quarter 2026 revenue momentum strengthens on higher diagnostic volumes and record product sales, alongside positive adjusted EBITDA and cash generation. | ||
Precipio Inc (PRPO) (Q2 2026) Earnings Call Highlights: Record Revenue and Positive EBITDA Mark ... Precipio Inc (PRPO) surpasses $7 million in quarterly revenue, achieves positive adjusted EBITDA, and generates strong operating cash flow. | ||
 Precipio, Inc. Q2 2026 Earnings Call Summary Moby summary of Precipio, Inc.'s Q2 2026 earnings call | ||
 PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy? Precipio and NeoGenomics take different approaches to cancer diagnostics, but which oncology stock looks more compelling now? Let's dive in. | ||